US FDA Delay For Abecma In Early MM Gives Carvykti Time To Catch Up
Bristol Myers and 2seventy bio are hoping Abecma will be the first CAR-T therapy for earlier lines of multiple myeloma, but an advisory committee meeting will hold up the sBLA.
You may also be interested in...
With slower than expected sales of some newer products, Bristol lowered mid-term guidance for its new product portfolio and extended the timeline for reaching the goal to 2026.
Johnson & Johnson delivered solid third quarter sales and earnings, which led the company to raise 2023 financial guidance.
Nearly two years after its spin-out from bluebird, 2Seventy is slowing in-house R&D and leaning on partners to conserve cash while BMS-partnered Abecma regains its competitive footing.